CD8A and metastatic melanoma: Therefore, we performed targeted exome sequencing and assessed the expression of TILs (CD8+) and tumour infiltrating B-cells (CD20+) in subtypes of 23 metastatic melanoma patients treated with ICI in order to explore their clinical impact as prognostic factors.